目的 觀察清咳平喘顆粒治療新型冠狀病毒感染（痰熱郁肺證）患者的臨床療效及安全性。方法 選取2022年3月—2022年6月在上海市公共衛(wèi)生臨床中心新冠病房住院的新型冠狀病毒感染（痰熱郁肺證）患者60例，根據(jù)治療藥物不同分為對(duì)照組和治療組，每組各30例。對(duì)照組給予常規(guī)治療，治療組患者在常規(guī)治療基礎(chǔ)上加用清咳平喘顆粒，10 g/次，3次/d。觀察兩組患者治療前后中醫(yī)證候療效、炎癥指標(biāo)及不良反應(yīng)。結(jié)果 治療后，治療組總有效率（86.7%）明顯高于對(duì)照組（66.7%）（P＜0.05）。治療后，兩組患者日間咳嗽評(píng)分和夜間咳嗽評(píng)分均低于治療前（P＜0.05），且治療組治療后日間咳嗽評(píng)分和夜間咳嗽評(píng)分均低于對(duì)照組（P＜0.05）。兩組患者治療前后外周血白細(xì)胞、降鈣素原水平比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后，兩組C反應(yīng)蛋白（CRP）水平較治療前顯著降低（P＜0.05），且治療后治療組CRP水平低于對(duì)照組（P＜0.05）。兩組不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 清咳平喘顆粒治療輕型、普通型新型冠狀病毒感染患者（痰熱郁肺證）具有較好的臨床療效，可緩解患者臨床癥狀，安全性較好。

Objective To observe the clinical efficacy and safety of Qingke Pingchuan Granules in treatment of light and common type of novel coronavirus infection (phlegm heat stagnating lung syndrome). Methods Sixty patients with novel coronavirus infection (phlegm heat stagnating lung syndrome) hospitalized in the Novel Coronavirus Unit of Shanghai Public Health Clinical Center from March 2022 to June 2022 were selected and divided into control group and treatment group according to different therapeutic drugs, with 30 cases in each group. Patients in the control group were given conventional treatment. Patients in the treatment group were po administered with Qingke Pingchuan Granules on the basis of conventional treatment, 10 g/time, 3 times daily. The efficacy of TCM syndromes, inflammatory indexes and adverse reactions were observed before and after treatment. Results After treatment, the total effective rate in the treatment group (86.7%) was significantly higher than that in the control group (66.7%) (P < 0.05). After treatment, daytime and nighttime cough scores in 2 groups were lower than before treatment (P < 0.05), and daytime and nighttime cough scores in the treatment group were lower than those in the control group (P < 0.05). There was no significant difference in the levels of peripheral blood leukocytes and procalcitonin between the two groups before and after treatment. After treatment, the level of C-reactive protein (CRP) in the two groups was significantly lower than that before treatment (P < 0.05), and the CRP level in the treatment group was lower than that in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Qingke Pingchuan Granules has good clinical efficacy in treatment of light and common type of novel coronavirus infection (phlegm heat stagnating lung syndrome), and can relieve the clinical symptoms of patients, which has good safety.

R974

上海市衛(wèi)生健康委員會(huì)面上項(xiàng)目（202040332）；上海市金山區(qū)醫(yī)藥衛(wèi)生科技創(chuàng)新資金項(xiàng)目（2022-WS-39）